UNSPSC 51432811: Saralasin acetate

This classification denotes an antihypertensive agent with the molecular formula C42H65N13O10.C2H4O2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FO21Z580M4. The term saralasin acetate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule saralasin acetate under HS 29371900 and SITC 54154. As of Q4 2014, SARALASIN ACETATE remains US FDA's Preferred Term for this commodity. Saralasin acetate bears US NLM identifiers UMLS ID C0030114 and NCI Concept Code C66528.

SMILES: C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2C[NH]CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3CCC(CC3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC.CC(=O)O.O.

UNSPSC 51432811 Saralasin acetate, a Commodity code, nominally addresses a specific pharmaceutical ingredient, but recent state and local procurement activity shows little direct solicitation for this substance. State and local governments procuring under pharmaceutical and medication codes are instead buying finished advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products through cooperative purchasing arrangements and direct municipal procurement. The City of Tampa's Purchasing Department, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the kinds of issuing bodies active in this space—municipalities, state health agencies, and multi-state cooperative purchasing vehicles—each with different procurement approaches ranging from sealed competitive bids for immediate supply to market intelligence gathering and statewide contract frameworks.

Activity is concentrated in Texas, Minnesota, and Florida, with involvement from participating Oregon jurisdictions through MMCAP's multi-state vehicle. Recent representative opportunities include the City of Tampa's IFB for Advanced Life Support Medications (due April 8, 2026, estimated value $40,000) supplying Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials to Tampa Fire Rescue; the Texas HHS Commission's RFI (due April 3, 2026) exploring direct-to-manufacturer prescription programs; and MMCAP's RFP for Generic Multi Source Pharmaceuticals and OTC Products (due March 26, 2026) establishing statewide contracts through authorized wholesalers AmerisourceBergen, Cardinal Health, and Morris & Dickson. The code appears misaligned with actual procurement scope—vendors pursuing pharmaceutical supply to state and local buyers should focus on finished-goods frameworks, cooperative purchasing arrangements, and Fire/EMS medication supply contracts rather than bulk active pharmaceutical ingredients.